ライフサイエンスコーパス: allogeneic cell

1 /or epigenomic manipulation of autologous or allogeneic cells.

2 ize and eliminate infected, transformed, and allogeneic cells.

3 ns prevents macrophage-mediated rejection of allogeneic cells.

4 responses to pig cells are stronger than to allogeneic cells.

5 ith in vitro assays measuring the killing of allogeneic cells.

6 ber in vivo in response to immunization with allogeneic cells.

7 Each child received two infusions of the allogeneic cells.

8 when given before the first oral delivery of allogeneic cells.

9 F nor AH inhibited the CTL-mediated Lysis of allogeneic cells.

10 accinated with irradiated syngeneic tumor or allogeneic cells.

11 ed p24 following stimulation with irradiated allogeneic cells.

12 d-lymphocyte cultures against MHC-disparate (allogeneic) cells.

13 and the responses induced by the transfer of allogeneic cells, a murine model was used to characteriz

14 To assess the survival of allogeneic cells after blood transfusion or transplantat

15 cytes from BALB/c mice that were primed with allogeneic cells and conditioned with rapamycin in vivo

16 Control animals rejected allogeneic cells and remained diabetic.

17 ly immunosuppressive to allow engraftment of allogeneic cells and they rely largely on graft-versus-l

18 onding cells in co-culture with x-irradiated allogeneic cells and which cause regulatory effects when

19 renatal transplantation of congenic or fully allogeneic cells are identical.

20 Regenerative therapies that use allogeneic cells are likely to encounter immunological b

21 consequences of alloimmune stimulation when allogeneic cells are transplanted to the liver in compar

22 tion and to induce immune tolerance to these allogeneic cells, as daily anti-rejection therapy cannot

23 himerism (MC), defined as the persistence of allogeneic cells at low concentrations, is well document

24 ministration of HLA-DQA1 in conjunction with allogeneic cells at the time of priming or at the time o

25 MHCs) in PSCs is particularly attractive for allogeneic cell-based therapies.

26 ide when administered in combination with an allogeneic, cell-based granulocyte-macrophage colony-sti

27 are developing MHC class II (MHC II)-matched allogeneic, cell-based uveal melanoma vaccines that acti

28 pients 1) proliferate weakly to donor strain allogeneic cells but vigorously to third-party strain ce

29 t NK cells at a resting state readily reject allogeneic cells, but not the skin allografts.

30 t RAG(-/-) mice mount a specific response to allogeneic cells characterized by swelling and infiltrat

31 Allogeneic cells coated with anti-CTLA-4 Ab induced immu

32 versial, potentially limiting the success of allogeneic cell combination therapy (ACCT).

33 First, allogeneic cells convey risk reduction for recurrent mal

34 it is unclear whether priming with specific allogeneic cells could conversely elicit a viral peptide

35 Studies of cotransferred congenic and allogeneic cells demonstrated that bystander proliferati

36 eic transplanted thymi are not rejected, and allogeneic cells do not induce graft-versus-host disease

37 could be exploited therapeutically and that allogeneic cells engineered to express a chemorepellent

38 with T cell loss being sufficient for robust allogeneic cell engraftment.

39 ll (ESC) products, immunological barriers to allogeneic cells, functional maturation beyond just the

40 ration of polyinosinic:polycytidylic acid or allogeneic cells (graft versus host).

41 d by NSCs are functional and can costimulate allogeneic cells in a mixed lymphocyte reaction.

42 proliferate in response to several different allogeneic cells in addition to 3B11.

43 urface of sperm, allowing them to survive as allogeneic cells in the female reproductive tract despit

44 ersistence of small numbers of fetal-derived allogeneic cells in the mother.

45 mice also stimulated greater responses from allogeneic cells in vitro.

46 re stimulated in vitro with anti-CD3 or with allogeneic cells in vivo in the presence or absence of r

47 and macrophages in recognizing and rejecting allogeneic cells in vivo.

48 k alloreactivity against recipient and other allogeneic cells, indicating a favorable safety profile

49 When introducing allogeneic cells into chimeric recipients, concomitant t

50 r repair strategies may involve injection of allogeneic cells into inflamed regions of damaged tissue

51 n, we injected BLV-infected or mock-infected allogeneic cells into the shoulder of sheep in which an

52 o the host-vs-graft reaction toward injected allogeneic cells is also reduced.

53 r of HSCs (250 cells) and a subpopulation of allogeneic cells known to facilitate HSC engraftment (fa

54 (PSJLSV and BxSF11gSV) but could not kill an allogeneic cell line (C57SV).

55 nses, and these same effector cells can lyse allogeneic cell lines in vitro.

56 mune system is naturally exposed to maternal allogeneic cells, maternal antibodies, and pathogens.

57 Moreover, allogeneic cell membranes manipulated to express xenopro

58 Long-term engraftment of allogeneic cells necessitates eluding immune-mediated re

59 ng the first days of infection and show that allogeneic cells of the inoculum traffic from the vagina

60 nstrate that iNKT cells are not activated by allogeneic cells per se, but expand, both in vitro and i

61 ganisms (zooids) by 14 d whereas transfer of allogeneic cell populations lacking MCs had only minimal

62 In contrast, CTLA4-Ig, which targets B7 on allogeneic cells, promotes long-term engraftment in thes

63 demonstrate that TheraCyte encapsulation of allogeneic cells provides robust immune protection in tr

64 Immunomodulation with allogeneic cells rapidly and efficiently engineered to d

65 wever, in vivo priming of KbDb -/- mice with allogeneic cells resulted in strong CD8+ MHC class Ia-sp

66 (lasting >5 min) formed preferentially with allogeneic cells, resulting in diminished motility and s

67 Oral tolerance induced with allogeneic cells shares characteristics with antigen-spe

68 On the other hand, allogeneic cells show several advantages over autologous

69 atal chondrocytes (NChons) are an attractive allogeneic cell source for cartilage repair, but their c

70 cept for the use of NIKS keratinocytes as an allogeneic cell source for the formation of bioengineere

71 NIKS keratinocytes are an attractive allogeneic cell source for this application.

72 Allogeneic cell stimulation used as a cell therapy may b

73 olytic CMV-specific responses using specific allogeneic cell stimulation, to confirm that this techni

74 Allogeneic cell therapy enables preoperative production

75 Autologous and allogeneic cell therapy for ischemic heart disease show

76 Although allogeneic cell therapy should still be considered a "na

77 This biologic feature can be exploited in allogeneic cell therapy, and the recognition of "missing

78 progenitor cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immu

79 The capacity of killed or sonicated allogeneic cells to induce oral tolerance and enhance co

80 ell infusion revealed the early migration of allogeneic cells to peripheral lymphoid organs, with lat

81 tself to use of chimeric epidermis, cultured allogeneic cells, to provide short-term coverage, togeth

82 In allogeneic cell transfers, donor GFP+ splenocytes were d

83 fter either adult stem cell transplantation (allogeneic cell transplantation [ACT]; n = 18) or cord b

84 We used syngeneic and allogeneic cell transplantation assays based on F344 rec

85 Allogeneic cells transplanted directly to the liver do n

86 ight circumvent the limitations and risks of allogeneic cell transplants.

87 in other mouse strains primed with different allogeneic cell types, including endothelial cells.

88 er delayed-type hypersensitivity response to allogeneic cells upon challenge but had normal contact h

89 the primary effector cells in the killing of allogeneic cells via "missing self" recognition.

90 Higher doses of allogeneic cells were needed to produce equivalent engra

91 The partially MHC-matched allogeneic cells were not detected in the blood or most

92 ormaldehyde-fixed, UVB-treated, or sonicated allogeneic cells were tested to determine if dead cells

93 f grafts 7 days after i.p. immunization with allogeneic cells, when CTL responses in L-selectin(-/-)

94 mechanisms regulating the behavior of these allogeneic cells, which are central to clinical applicat

95 ion of the MLR and CML responses of the same allogeneic cells with 200 times fewer modulator cells ne

96 e distinctive patterns of reactivity against allogeneic cells with different haplotypes.

97 The combination of prenatal tolerance to allogeneic cells with postnatal boosts in primed hosts m

98 the ability to implant either xenogeneic or allogeneic cells would greatly enhance the clinical appl